CoChat

Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer

Sawada, Kentaro, Nakamura, Yoshiaki, Yamanaka, Takeharu, Kuboki, Yasutoshi, Yamaguchi, Daisuke, Yuki, Satoshi, Yoshino, Takayuki, Komatsu, Yoshito, Sakamoto, Naoya, Okamoto, Wataru, Fujii, Satoshi · 2018 · Clinical Colorectal Cancer
Cited by 85

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Micro‐Abstract: We evaluated the prognostic impact of human epidermal growth factor receptor 2 (HER2) amplification in metastatic colorectal cancer as well as the efficacy of anti–epidermal growth factor receptor (EGFR) therapy. HER2 amplification was as potentially prognostic for overall survival as RAS or BRAFV600E mutation as well as a potential negative predictive factor of anti‐EGFR therapy in metastatic colorectal cancer. Purpose: To evaluate a prognostic and predictive value of HER2 amplification in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Patients with mCRC who underwent surgical resection of the primary tumor and who received best supportive care with or without palliative chemotherapy between 2005 and 2015 were included. HER2 immunohistochemistry was performed using formalin‐fixed, paraffin‐embedded primary tumor specimens. HER2 amplification was confirmed by fluorescence in‐situ hybridization. The RAS and BRAFV600E mutations were centrally assessed using a PCR‐based method. Patients were divided into 4 subgroups: R (RAS mutant), B (BRAFV600E mutant), H (wild‐type RAS/BRAF with HER2 amplification), and W (wild‐type RAS/BRAF without HER2 amplification). Overall survival (OS) and progression‐free survival of anti–epidermal growth factor receptor (EGFR) therapy were assessed. Results: Among 370 eligible patients, data of 359 were successfully analyzed. Fifteen tumors harbored HER2 amplifications, including 4 tumors with concomitant RAS mutation (group R). The number of patients in groups R, B, H, and W was 204, 13, 11, and 131, respectively. The median OS was 27.4 months, and the median follow‐up time was 63.2 months. The median OS for groups R, B, H, and W was 24.0, 14.2, 19.9, and 39.1 months, respectively. The number of patients who received anti‐EGFR therapy in groups R, B, H, and W was 17, 4, 5, and 49, respectively. Progression‐free survival of anti‐EGFR therapy was significantly shorter in groups R, B, and H than in group W. Conclusion: HER2 amplification was predictive of anti‐EGFR therapy response and appeared to be prognostic in mCRC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clcc.2018.05.006

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 85

Metadata

Authors
Sawada, K., Nakamura, Y., Yamanaka, T., Kuboki, Y., Yamaguchi, D., Yuki, S., Yoshino, T., Komatsu, Y., Sakamoto, N., Okamoto, W., & Fujii, S.
Venue
Clinical Colorectal Cancer
Publisher
Elsevier BV
Published
2018-09
Volume
17
Issue
3
Pages
198-205
ISSN
1533-0028 (ISSN-L)
OpenAlex
W2804245532
Cited by
85
References
11
FWCI
2.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.